RGNX – REGENXBIO Inc.
REGENXBIO Inc.RGNX
$5.94Name : REGENXBIO Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $297,694,400.00
EPSttm : -4.59
REGENXBIO Inc.
$5.94
3.57%$0.22Float Short %
11.54
Margin Of Safety %
Put/Call OI Ratio
0.46
EPS Next Q Diff
0.24
EPS Last/This Y
3.61
EPS This/Next Y
0.26
Price
5.94
Target Price
33.85
Analyst Recom
1.38
Performance Q
-16.92
Relative Volume
0.71
Beta
1.19
Ticker: RGNX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-20 | RGNX | 8.36 | 0.45 | 0.09 | 3712 |
| 2025-03-21 | RGNX | 8.24 | 0.45 | 8.67 | 3700 |
| 2025-03-24 | RGNX | 8.69 | 0.52 | 0.10 | 3178 |
| 2025-03-25 | RGNX | 8.22 | 0.49 | 0.80 | 3325 |
| 2025-03-26 | RGNX | 8.21 | 0.49 | 0.00 | 3346 |
| 2025-03-27 | RGNX | 7.91 | 0.47 | 1.64 | 3451 |
| 2025-03-28 | RGNX | 7.82 | 0.50 | 5.40 | 3548 |
| 2025-03-31 | RGNX | 7.16 | 0.51 | 0.79 | 3569 |
| 2025-04-01 | RGNX | 6.75 | 0.50 | 0.06 | 3643 |
| 2025-04-02 | RGNX | 7.05 | 0.50 | 0.00 | 3662 |
| 2025-04-03 | RGNX | 6.69 | 0.48 | 17.67 | 3667 |
| 2025-04-04 | RGNX | 6.29 | 0.50 | 0.77 | 3723 |
| 2025-04-07 | RGNX | 5.93 | 0.50 | 0.32 | 3723 |
| 2025-04-08 | RGNX | 5.31 | 0.50 | 2.00 | 3720 |
| 2025-04-09 | RGNX | 5.91 | 0.51 | 1.26 | 3731 |
| 2025-04-10 | RGNX | 5.39 | 0.49 | 1.03 | 3795 |
| 2025-04-11 | RGNX | 5.88 | 0.49 | 0.03 | 3828 |
| 2025-04-14 | RGNX | 6.33 | 0.48 | 11.00 | 3866 |
| 2025-04-15 | RGNX | 6.55 | 0.48 | 0.00 | 3879 |
| 2025-04-16 | RGNX | 6.16 | 0.48 | 999.99 | 3891 |
| 2025-04-17 | RGNX | 5.92 | 0.46 | 0.00 | 3834 |
| 2025-04-18 | RGNX | 5.94 | 0.46 | 0.00 | 3834 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-20 | RGNX | 8.36 | 10.7 | 328.0 | -1.29 |
| 2025-03-21 | RGNX | 8.22 | 10.7 | 327.9 | -0.98 |
| 2025-03-24 | RGNX | 8.70 | 125.4 | 341.3 | -0.98 |
| 2025-03-25 | RGNX | 8.21 | 125.4 | 320.9 | -0.98 |
| 2025-03-26 | RGNX | 8.20 | 125.4 | 331.0 | -0.98 |
| 2025-03-27 | RGNX | 7.91 | 125.4 | 324.5 | -0.98 |
| 2025-03-28 | RGNX | 7.83 | 125.4 | 329.3 | -0.98 |
| 2025-03-31 | RGNX | 7.15 | 125.4 | 314.7 | -0.98 |
| 2025-04-01 | RGNX | 6.76 | 125.4 | 320.0 | -0.98 |
| 2025-04-02 | RGNX | 7.05 | 125.4 | 340.2 | -0.98 |
| 2025-04-03 | RGNX | 6.67 | 125.4 | 320.3 | -0.98 |
| 2025-04-04 | RGNX | 6.28 | 125.4 | 318.9 | -0.98 |
| 2025-04-07 | RGNX | 5.93 | 125.4 | 318.5 | -0.98 |
| 2025-04-08 | RGNX | 5.31 | 125.4 | 306.5 | -0.98 |
| 2025-04-09 | RGNX | 5.91 | 125.4 | 362.2 | -0.98 |
| 2025-04-10 | RGNX | 5.38 | 125.4 | 310.5 | -0.98 |
| 2025-04-11 | RGNX | 5.88 | 125.4 | 354.7 | -0.98 |
| 2025-04-14 | RGNX | 6.33 | 125.4 | 349.5 | -0.98 |
| 2025-04-15 | RGNX | 6.55 | 125.4 | 339.1 | -0.98 |
| 2025-04-16 | RGNX | 6.15 | 125.4 | 318.0 | -0.98 |
| 2025-04-17 | RGNX | 5.94 | 125.4 | 322.8 | -0.98 |
| 2025-04-18 | RGNX | 5.94 | 125.4 | 331.0 | -0.98 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-20 | RGNX | -0.20 | -4.81 | 13.90 |
| 2025-03-21 | RGNX | -0.20 | -4.81 | 13.90 |
| 2025-03-24 | RGNX | -0.20 | -4.86 | 13.90 |
| 2025-03-25 | RGNX | -0.20 | -4.86 | 13.90 |
| 2025-03-26 | RGNX | -0.20 | -4.86 | 13.38 |
| 2025-03-27 | RGNX | -0.20 | -4.86 | 13.38 |
| 2025-03-28 | RGNX | -0.20 | -4.86 | 13.38 |
| 2025-03-31 | RGNX | -0.20 | -4.85 | 13.38 |
| 2025-04-01 | RGNX | -0.20 | -4.85 | 13.38 |
| 2025-04-02 | RGNX | -0.20 | -4.85 | 13.38 |
| 2025-04-03 | RGNX | 0.00 | -4.85 | 13.38 |
| 2025-04-04 | RGNX | 0.00 | -4.85 | 13.38 |
| 2025-04-07 | RGNX | 0.00 | -4.96 | 13.39 |
| 2025-04-08 | RGNX | 0.00 | -4.96 | 13.39 |
| 2025-04-09 | RGNX | 0.00 | -4.96 | 13.39 |
| 2025-04-10 | RGNX | 0.00 | -4.96 | 11.55 |
| 2025-04-11 | RGNX | 0.00 | -4.96 | 11.55 |
| 2025-04-14 | RGNX | 0.00 | -4.97 | 11.54 |
| 2025-04-15 | RGNX | 0.00 | -4.97 | 11.54 |
| 2025-04-16 | RGNX | 0.00 | -4.97 | 11.54 |
| 2025-04-17 | RGNX | 0.00 | -4.97 | 11.54 |
| 2025-04-18 | RGNX | 0.00 | -4.97 | 11.54 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.01
Avg. EPS Est. Current Quarter
0.34
Avg. EPS Est. Next Quarter
-0.77
Insider Transactions
Institutional Transactions
-4.97
Beta
1.19
Average Sales Estimate Current Quarter
105
Average Sales Estimate Next Quarter
35
Fair Value
Quality Score
39
Growth Score
31
Sentiment Score
21
Actual DrawDown %
88.2
Max Drawdown 5-Year %
-89.4
Target Price
33.85
P/E
Forward P/E
PEG
P/S
3.57
P/B
1.13
P/Free Cash Flow
EPS
-4.64
Average EPS Est. Cur. Y
-0.98
EPS Next Y. (Est.)
-0.73
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-272.54
Relative Volume
0.71
Return on Equity vs Sector %
-107.4
Return on Equity vs Industry %
-94.1
EPS 1 7Days Diff
-0.6
EPS 1 30Days Diff
-0.55
EBIT Estimation
331
REGENXBIO Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 353
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today
news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance
stock history RGNX – REGENXBIO Inc. invest stock market
stock prices RGNX premarket after hours
ticker RGNX fair value insiders trading